Brian Gaupp
Hematology & Oncology · Thomasville, GANPI 1649265430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in GA, where the typical reported total is $4,479.
Across 69 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$141
- Novartis$128
- AstraZeneca$95
- Merck$93
- Johnson & Johnson$88
- Sanofi$74
- plus $539 from 19 others
What the payments were for
- Food & beverage$1,13498%
- Education$242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $141 |
| Novartis | 7 | $128 |
| AstraZeneca(2 entities) | 6 | $95 |
| Merck | 5 | $93 |
| Johnson & Johnson | 5 | $88 |
| Sanofi | 4 | $74 |
| Gilead | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| GSK | 2 | $37 |
| Exelixis Inc. | 2 | $33 |
| Eisai Inc. | 2 | $31 |
| Rigel Pharmaceuticals, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Bristol Myers Squibb | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Pfizer | 2 | $26 |
| Veran Medical Technologies, Inc. | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Seagen Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $16 |
| Array Biopharma Inc | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$1,158 in reported general payments places this provider in the 25th percentile of 370 hematology & oncology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 11 | $147,556 |
| Anastrozole | 54 | $1,018 |
| Potassium Chloride | 14 | $357 |
| Tamoxifen Citrate | 15 | $231 |
| Prednisone | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $12 | $147,55611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Thomasville
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.